2025 Independent Director Work Report-Yuan Huagang
Zhengzhou Antu Bioengineering Co., Ltd.
2025 Independent Directors’ Work Report
(Yuan Huagang)
As an independent director of Zhengzhou Antu Bioengineering Co., Ltd. (hereinafter referred to as the "Company"), in 2025, I strictly followed the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Measures for the Administration of Independent Directors of Listed Companies and other laws and regulations and the Articles of Association, performed my duties diligently, faithfully performed my duties, actively attended relevant meetings, gave full play to my independent role as an independent director, and safeguarded the overall interests of the company and the legitimate rights and interests of small and medium-sized shareholders.
I will serve as an independent director of the company on October 28, 2024. I would like to report on my main work in 2025 as follows:
1. Basic information of independent directors
(1) Personal work resume, professional background and part-time job status
Mr. Yuan Huagang, Han nationality, Chinese nationality, without permanent residence abroad, was born in 1973. He holds a bachelor's degree in economics from Zhejiang University and an MBA from the University of Macau. He has passed the domestic lawyer qualification and sponsor representative qualification examinations and has been engaged in mergers, acquisitions, restructuring and various innovative businesses for a long time. Mr. Yuan Huagang served as executive director, managing director, deputy general manager and sponsor representative of the investment banking department of Guotai Junan Securities Co., Ltd., managing partner of Zhejiang Private Enterprise United Investment Co., Ltd., and director and general manager of Pais Shuanglin Biopharmaceutical Co., Ltd. (SZ.000403). He currently serves as senior vice president of Huizhou Yiwei Lithium Energy Co., Ltd. (SZ.300014), independent director of Shanghai Xinhua Media Co., Ltd. (SH.600625), independent director of Hangzhou Tigermed Pharmaceutical Technology Co., Ltd. (SZ.300347), and director of Beijing Futian Yiwei New Energy Technology Co., Ltd. He will serve as an independent director of the company from October 28, 2024.
(2) Description of independence
As an independent director of the company, neither I nor my immediate family members or major social relations directly or indirectly hold shares in the company. I do not hold any position in a shareholder unit that directly or indirectly holds 5% or more of the company's issued shares. I have not obtained additional, undisclosed interests from the company and its major shareholders or interested institutions and personnel. I have the independence required by laws and regulations, and there are no circumstances that affect independence.
2. Annual performance overview of independent directors
(1) Attendance at board of directors and shareholders (meetings)
In 2025, the company held a total of 7 board of directors and 3 shareholders (general meetings). My attendance details are as follows:
Name of participating shareholder (largest) Participation in the board of directors
meeting situation
Page 1 of 5
Should attend this year. Attend in person. Communication method. Proxy. Absent. Number of times to attend the shareholder (general) board of directors. Number of times. Number of attendance. Number of seats. Number of meetings.
Yuan Huagang 7 7 7 0 0 3
During my tenure, I attended board meetings on time in accordance with relevant systems and carefully reviewed various proposals. Before convening the board of directors, I took the initiative to obtain the information needed to make decisions, and had a detailed understanding of the company's entire production operations and operating conditions. On this basis, I exercised my voting rights independently, objectively and prudently. In particular, I maximized my professional knowledge and work experience in the company's internal control, operations and management, and put forward opinions and suggestions seriously and responsibly. I believe that during my term of office, the convening of the company's board of directors complied with legal procedures, and all major matters went through relevant approval procedures and were legal and valid. Therefore, I voted in favor of all the resolutions of the board of directors, and there were no objections, objections, or abstentions.
(2) Attendance at special committees and special meetings of independent directors
During my term of office, in accordance with the "Articles of Association", "Working Rules of Special Committees of the Board of Directors" and other relevant regulations, I actively participated in the meetings of various special committees, used my own experience and knowledge to actively carry out work, conscientiously performed my duties, provided suggestions for the efficient and scientific decision-making of the Board of Directors, and ensured the smooth progress of major matters of the company. My attendance at the meetings of the special committees of the Board of Directors is as follows:
Category of special committee Number of meetings held during the term Number of meetings that should be attended Number of actual attendance Number of entrusted attendance Audit Committee 7 7 7 0
Strategic Development Committee 1 1 1 0
During his term of office, the company did not involve matters that required convening special meetings of independent directors for review.
(3) Exercising the powers of independent directors
During my tenure, in order to fully understand the company's operations and standardized operations, I conducted full on-site inspections of the company's office space, construction progress of investment projects, and the company's subsidiary Shenzhen Antu to gain an in-depth understanding of the company's management status, financial status and other major matters.
The company's management attaches great importance to communication with me, actively reports on the progress of major matters related to the company's production and operations, solicits my professional opinions, and implements the suggestions in a timely manner, providing the necessary conditions and support for better performance of duties. During my tenure, I maintained close contact with the company's directors, senior managers and relevant staff through various methods such as on-site meetings and communications. I communicated more than 50 times. Especially in terms of the company's accounting processing, I communicated in depth with the company's financial director and reached consensus.
(4) Communication with internal audit institutions and accounting firms
During my tenure, I maintained close communication with the company’s internal audit agency and annual audit accounting firm, and paid close attention to the company’s financial performance in a timely manner.
Page 2 of 5 financial status, daily operations, business development, etc.; at the same time, maintain active communication with external audit institutions, participate in annual external audit progress, summary and plan communication meetings, understand the annual audit plan and specific arrangements, fully communicate with accountants on key audit matters involved in the company, promote and supervise the role of internal audit institutions and accounting firms, and safeguard the interests of all shareholders of the company.
(5) Communication with small and medium-sized shareholders
During my tenure, I communicated with small and medium-sized shareholders by participating in the company's performance briefings and attending the company's shareholders (general meeting). In addition, the company maintains communication with small and medium-sized shareholders through various channels such as performance briefings, IR calls, and emails, and relays relevant opinions and suggestions to me. I have listened extensively to the opinions and suggestions of small and medium-sized shareholders, and effectively safeguarded the legitimate rights and interests of all shareholders, especially small and medium-sized shareholders.
(6) On-site work and company cooperation
During my tenure, with the company's active cooperation, I conducted on-site inspections and supervision on the company's production and operation, financial situation, information disclosure management, construction and operation of internal control systems, and the implementation of board resolutions through on-site surveys, on-site meetings, communication meetings, emails and WeChat and other matters. I also actively understood the company's market development prospects, investment project construction, internal control management and other operating dynamics, paid close attention to corporate governance, production and operation management and development, and actively and effectively performed the duties of an independent director. Before convening relevant meetings, the company has timely and accurately delivered meeting documents and materials, and provided feedback on all opinions and suggestions put forward, providing necessary conditions and sufficient support for me to perform my duties as an independent director, and ensuring that I have the same right to know as other directors.
I strictly abide by relevant laws, regulations and the company's articles of association for independent directors to perform their duties. During the reporting period, the cumulative on-site work time was 15 days. The work content included but was not limited to attending meetings, reviewing materials, communicating with all parties and other work related to this report.
3. Matters of focus in annual performance of duties
(1) Related transactions
In accordance with the provisions of the "Code of Corporate Governance for Listed Companies", the "Articles of Association" and relevant laws and regulations, based on my independent judgment, I believe that the related transactions that occurred during the reporting period of the company follow the principles of fairness, justice and fairness and will not harm the interests of the company and small and medium-sized shareholders, nor will it affect the independence of the company.
(2) Plans for listed companies and relevant parties to change or waive their commitments
During my tenure, there will be no changes or exemptions from commitments by the company and related parties.
(3) Decisions made and measures taken by the board of directors of the acquired listed company regarding the acquisition
During my tenure, I was not involved in the acquisition of the company.
Page 3 of 5
(4) Disclosure of financial information in financial accounting reports and periodic reports, and internal control evaluation reports
During my tenure, I paid close attention to and supervised the financial information in the company's financial accounting reports and four periodic reports. I believe that the financial information in the company's financial accounting reports and periodic reports truly, accurately and completely reflects the actual situation of the company, and there are no false records, misleading statements or major omissions.
In addition, the company has completed the construction and evaluation of the internal control system in accordance with the requirements of the "Basic Standards for Enterprise Internal Control" and its supporting guidelines, and organized and implemented it in accordance with the "Company Internal Control Management Manual". I believe that the content and form of the internal control evaluation report disclosed by the company during my tenure are in compliance with relevant regulations and objectively, truly and accurately reflect the current internal control status of the company. The external audit institution Zhongqin Wanxin Accounting Firm (Special General Partnership) audited the effectiveness of the company's internal control over financial reporting and believed that the company maintained effective internal control over financial reporting in all material aspects.
(5) Appointment and dismissal of accounting firms that undertake the audit business of listed companies
During his tenure, the company held the fourth meeting of the fifth board of directors and the 2024 annual shareholders (general meeting), and reviewed and approved the "Proposal on Renewal of the Company's Audit Institution for 2025". After verification, I believe that Zhongqin Wanxin Certified Public Accountants (Special General Partnership) was able to follow independent, objective and fair practice standards, carry out audit work conscientiously and solidly, and complete various audit tasks well during the company's 2024 special audit and financial statement audit. I agree to re-appoint Zhongqin Wanxin Certified Public Accountants (Special General Partnership) as the company's auditor for 2025, and agree to submit it to the company's 2024 annual shareholders (general meeting) for review.
(6) Appointment or dismissal of the company’s financial director
During my tenure, the company did not engage in the appointment or dismissal of the company's financial director.
(7) Changes in accounting policies, accounting estimates or correction of major accounting errors due to reasons other than changes in accounting standards
The company held the fourth meeting of the fifth board of directors on April 16, 2025, and reviewed and approved the "Proposal on Changes in Accounting Estimates." After verification, I believe that this change in accounting estimates will more objectively and fairly reflect the company's financial status and operating results, and is more in line with relevant laws, regulations and "Accounting Standards for Business Enterprises No. 28 - Accounting Policies, Accounting Estimate Changes and Error Corrections" and other provisions, and will not harm the interests of the company and all shareholders, especially small and medium-sized shareholders.
(8) Nominate or appoint or remove directors, hire or dismiss senior managers
During his tenure, the company held the third meeting of the fifth board of directors on January 21, 2025, and reviewed and approved the "Proposal on Nominating Candidates for the Sub-election of Independent Directors and Adjusting the Members of Relevant Special Committees of the Board of Directors". I believe that the independent director candidates for by-election have the necessary professional knowledge and abilities to perform relevant duties, and their qualifications are in compliance with relevant regulations such as the Company Law of the People's Republic of China, the Stock Listing Rules of the Shanghai Stock Exchange and the Articles of Association. The board of directors' review procedures are legal and effective.
Page 4 of 5
(9) Remuneration of directors and senior managers, formulating or changing equity incentive plans, employee stock ownership plans, etc.
During his tenure, the company held the fourth meeting of the fifth board of directors on April 16, 2025. All directors abstained from voting on the "Proposal on the Remuneration Plan for Directors and Senior Management Personnel" and directly submitted it to the company's 2024 annual shareholders' (general) meeting for review. I believe that this decision-making process complies with the requirements of the "Shanghai Stock Exchange Stock Listing Rules" and "Code of Governance of Listed Companies" and other regulations, and the board of directors' review procedures are legal and effective.
During the reporting period, the company did not implement equity incentive measures such as equity incentive plans and employee stock ownership plans.
4. Overall evaluation and suggestions
In 2025, as an independent director of the company, I strictly followed the requirements of relevant laws and regulations, and with a responsible attitude towards the company and all shareholders, actively investigated and carefully analyzed the company's production and operating conditions through various methods, attended the company's board of directors and shareholders (general) meetings on time, carefully studied the relevant proposals that need to be reviewed by the board of directors, and exercised my voting rights in a prudent and responsible manner, which played a positive role in promoting the scientific decision-making of the board of directors, promoting the company's standardized operations, and safeguarding the legitimate rights and interests of the company and all shareholders. I and the other three independent directors conducted self-evaluations and mutual evaluations on the performance of their duties in 2025, and the evaluation results were all competent.
In 2026, I will continue to perform my duties as an independent director independently, impartially, prudently, conscientiously, diligently and faithfully, and rely on my professional knowledge and experience to provide the company with more positive and effective opinions and suggestions, promote the continuous improvement of the company's scientific decision-making level, and effectively safeguard the overall interests of the company and the legitimate rights and interests of small and medium-sized shareholders.
Independent Director of Zhengzhou Antu Bioengineering Co., Ltd.: Yuan Huagang
April 21, 2026
Page 5 of 5